Kamalian Laleh, Douglas Oisin, Jolly Carol E, Snoeys Jan, Simic Damir, Monshouwer Mario, Williams Dominic P, Park B Kevin, Chadwick Amy E
MRC Centre for Drug Safety Science, The Department of Clinical and Molecular Pharmacology, The University of Liverpool, Liverpool, United Kingdom.
Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Beerse, Belgium.
Curr Protoc Toxicol. 2019 Jun;80(1):e76. doi: 10.1002/cptx.76. Epub 2019 May 6.
Using galactose instead of glucose in the culture medium of hepatoma cell lines, such as HepG2 cells, has been utilized for a decade to unmask the mitochondrial liability of chemical compounds. A modified glucose-galactose assay on HepG2 cells, reducing the experimental period for screening of mitochondrial toxicity to 2 to 4 hr, has been previously reported. HepaRG cells are one of the few cell lines that retain some of the important characteristics of human hepatocytes, offering advantages of working with a cell line, therefore, are considered an alternative for HepG2 cells in drug toxicity screening. A method is described here using HepaRG cells in an acute metabolic switch assay utilizing specific glucose/galactose media, a combined ATP-protein-LDH assay measuring three endpoints from one 96-well plate, and a criteria to label a compound as a mitochondrial toxin. © 2019 by John Wiley & Sons, Inc.
在肝癌细胞系(如HepG2细胞)的培养基中使用半乳糖替代葡萄糖,已被用于揭示化合物的线粒体易感性长达十年之久。此前已有报道称,对HepG2细胞进行改良的葡萄糖 - 半乳糖检测,可将线粒体毒性筛选的实验周期缩短至2至4小时。HepaRG细胞是少数保留人类肝细胞一些重要特征的细胞系之一,具有使用细胞系的优势,因此被认为是药物毒性筛选中HepG2细胞的替代选择。本文描述了一种方法,该方法使用HepaRG细胞进行急性代谢转换检测,利用特定的葡萄糖/半乳糖培养基,通过一种结合ATP - 蛋白质 - LDH的检测方法从一个96孔板中测量三个终点指标,并制定了将化合物标记为线粒体毒素的标准。© 2019约翰威立父子出版公司